180 related articles for article (PubMed ID: 30454872)
1. Long-Term Follow-Up of
Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
[TBL] [Abstract][Full Text] [Related]
2. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Gopal AK; Guthrie KA; Rajendran J; Pagel JM; Oliveira G; Maloney DG; Matesan MC; Storb RF; Press OW
Blood; 2011 Jul; 118(4):1132-9. PubMed ID: 21508413
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
[TBL] [Abstract][Full Text] [Related]
4. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Bouabdallah K; Furst S; Asselineau J; Chevalier P; Tournilhac O; Ceballos P; Vigouroux S; Tabrizi R; Doussau A; Bouabdallah R; Mohty M; Le Gouill S; Blaise D; Milpied N
Ann Oncol; 2015 Jan; 26(1):193-198. PubMed ID: 25361987
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
6. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
Khouri IF; Saliba RM; Erwin WD; Samuels BI; Korbling M; Medeiros LJ; Valverde R; Alousi AM; Anderlini P; Bashir Q; Ciurea S; Gulbis AM; de Lima M; Hosing C; Kebriaei P; Popat UR; Fowler N; Neelapu SS; Samaniego F; Champlin RE; Macapinlac HA
Blood; 2012 Jun; 119(26):6373-8. PubMed ID: 22586182
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Fietz T; Uharek L; Gentilini C; Muessig A; Rieger K; Marinets O; Sandrock D; Munz DL; Glass B; Thiel E; Blau IW
Leuk Lymphoma; 2006 Jan; 47(1):59-63. PubMed ID: 16321828
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Sauter CS; Barker JN; Lechner L; Zheng J; Devlin SM; Papadopoulos EB; Perales MA; Jakubowski AA; Goldberg JD; Koehne G; Ceberio I; Giralt S; Zelenetz AD; Moskowitz CH; Castro-Malaspina H
Biol Blood Marrow Transplant; 2014 Mar; 20(3):354-60. PubMed ID: 24315843
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
[TBL] [Abstract][Full Text] [Related]
13. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Bethge WA; Lange T; Meisner C; von Harsdorf S; Bornhaeuser M; Federmann B; Stadler M; Uharek L; Stelljes M; Knop S; Wulf G; Trenschel R; Vucinic V; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
Blood; 2010 Sep; 116(10):1795-802. PubMed ID: 20530284
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
Chen GL; Hahn T; Wilding GE; Groman A; Hutson A; Zhang Y; Khan U; Liu H; Ross M; Bambach B; Higman M; Neppalli V; Sait S; Block AW; Wallace PK; Singh AK; McCarthy PL
Biol Blood Marrow Transplant; 2019 Apr; 25(4):689-698. PubMed ID: 30300731
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Gopal AK; Gooley TA; Rajendran JG; Pagel JM; Fisher DR; Maloney DG; Appelbaum FR; Cassaday RD; Shields A; Press OW
Biol Blood Marrow Transplant; 2014 Jun; 20(6):770-5. PubMed ID: 24530971
[TBL] [Abstract][Full Text] [Related]
18. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Bone Marrow Transplant; 2008 Feb; 41(4):355-61. PubMed ID: 18026153
[TBL] [Abstract][Full Text] [Related]
19. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Chow VA; Cassaday RD; Gooley TA; Smith SD; Sandmaier BM; Green DJ; Orozco JJ; Tuazon SA; Matesan M; Fisher DR; Maloney DG; Press OW; Gopal AK
Blood Adv; 2022 Jan; 6(1):37-45. PubMed ID: 34649272
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine/Melphalan 100 mg/m
Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]